All the news Showing 10 of 135 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir Gilead press release / 27 October 2016 Sofosbuvir/velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications IQWIG / 17 October 2016 Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV Achillion press release / 26 September 2016 NICE says yes to another hepatitis C drug NICE / 26 September 2016 Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV Achillion press release / 09 September 2016 European Commission Grants Marketing Authorisation for MSD’s ZEPATIER™ (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection MSD press release / 02 August 2016 European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C Gilead press release / 08 July 2016 Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union MSD press release / 30 May 2016 RG-101 Interim Analysis Shows 97% Response at 8 Week Follow-Up Regulus Therapeutics press release / 17 February 2016 Australia: Treatment Has Changed campaign Hepatitis New South Wales / 17 February 2016 ← First12345...14Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive